CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models
Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy.
Authors
- Konstantinos Vazaios (ORCID: https://orcid.org/0000-0002-3623-0348)
- Benjamin Schwalm
- Piotr Waranecki (ORCID: https://orcid.org/0000-0002-0133-9490)
- Antonio Carlos Tallon-Cobos
- Eelco W. Hoving (ORCID: https://orcid.org/0000-0002-5587-0439)
- Dennis S. Metselaar (ORCID: https://orcid.org/0000-0001-5559-2435)
- Annelisa M. Cornel (ORCID: https://orcid.org/0000-0001-8349-121X)
- Esther Hulleman (ORCID: https://orcid.org/0000-0001-9256-947X)
- Marcel Kool (ORCID: https://orcid.org/0000-0002-6557-5468)
- Jasper van der Lugt (ORCID: https://orcid.org/0000-0002-8186-338X)
- Stefan Nierkens (ORCID: https://orcid.org/0000-0003-3406-817X)
- Marliek van Hoesel
- Norman Mack
- Ella de Boed
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Medical Center Utrecht (NL)
- Hopp Children's Cancer Center Heidelberg (DE)
- Princess Máxima Center (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1172/jci193332
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00